Inactive Instrument

Press Releases Can Fite Biopharma Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0010944739

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Can Fite BioPharma : Fite Presentation	Jul. 08	PU
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	Jul. 01	AQ
Can Fite BioPharma : Other Report or Announcement	Jun. 28	PU
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix	Jun. 28	BU
Can Fite BioPharma : Other Report or Announcement	Jun. 26	PU
Can Fite BioPharma : Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	Jun. 24	PU
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	Jun. 24	BU
Can Fite BioPharma : Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	Jun. 10	PU
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	Jun. 10	BU
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study	Jun. 05	BU
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	May. 29	BU
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024	May. 27	BU
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6	May. 23	BU
Can Fite BioPharma : Immediate Report of Meeting	May. 22	PU
Can Fite BioPharma : NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	May. 22	PU
Can Fite BioPharma : Immediate Report	May. 13	PU
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	May. 13	BU
CAN-FITE, FDA GRANTS IND CLEARANCE FOR NAMODENOSON TO TREAT MASH PATIENTS IN A PHASE IIB STUDY	May. 10	AQ
Can Fite BioPharma : FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	May. 09	PU
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	May. 09	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Can Fite Biopharma Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0010944739

Press Releases

Filters